A 22-year-old woman with severe Graves' disease was referred from a local clinic because of her refractory hyperthyroidism. She presented with exophthalmos, diffuse goiter, and tachycardia. She was treated with a maximal dose of methimazole and a beta-blocker for 2 months. However, her thyroid function test (TFT) did not improve. TFT showed a free T4 level of 74.7 ng/dL and a thyroid stimulating hormone (TSH) level of 0.007 μIU/mL. She was then administered cholestyramine (4 g thrice daily), hydrocortisone (300 mg/day) and methimazole (100 mg/day) which prepared the patient for surgery by reducing the free T4 level (4.7 ng/dL). The patient underwent a total thyroidectomy without experiencing thyrotoxic crisis. This case describes the use of cholestyramine for the first time in Korea in treating Graves' disease and provides limited evidence that cholestyramine can be an effective option.
Introduction
The most common cause of hyperthyroidism is Graves' disease. It is an autoimmune disorder characterized by a constellation of clinical features including hyperthyroidism, diffuse goiter, ophthalmopathy, and dermopathy.
1) The therapeutic approach to Graves' disease consists of treatment with a beta-blocker, which results in both a rapid amelioration of symptoms and a decrease in thyroid hormone synthesis. Usually
Graves' disease responds well to treatment with the antithyroid drugs; propylthiouracil (PTU) and methimazole (MMI) or its pro-drug, carbimazole. If these drugs are not effective, then surgery or radioiodine therapy must be considered. However, radioactive iodine is reluctant to use to women of childbearing age.
Furthermore, there is increasing evidence that radioactive iodine can worsen ophthalmopathy resulting from Graves' disease compared to treatment with antithyroid drugs or surgery. 2) In the case of thyroidectomy, the patient's free T4 level needs to be near or at normal before surgery to prevent a post-operative thyroid storm. Thus, adjunctive treatment in the form of beta-blockers, corticosteroids, or inorganic iodide may also be used for more prompt control of symptoms prior to surgery.
3) Nevertheless, we often encounter the patients who are resistant to antithyroid drugs and adjunctive therapy. Certain studies have indicated that bile acid sequestrants, when administered with antithyroid drugs, produce a more rapid decline in serum thyroid hormone levels. [4] [5] [6] However, there has been no report in Korea regarding the effect of treatment with cholestyramine. Here, we report a successful case of cholestyramine treatment prior to surgery in a patient resistant to MMI. TBII was tested 2 months before admission and it was 29.2 U/L (0-9.9 U/L). It wasn't rechecked thereafter). The thyroid scintigraphy scan showed homogeneously increased Tc-99m uptake (thyroid uptake:
29.4%) (Fig. 1) . Ultrasound image revealed a diffusely enlarged gland without any nodule or mass. After the patient was admitted, she was administered 3 drops of Lugol's solution thrice daily (0.45 cc in total), 100 mg of MMI (the dose was decided mainly upon the expert's opinion), 7) 120 mg of propranolol, and 300 mg of hydrocortisone daily. PTU was once given but she complained of severe nausea and pruritus after taking it. So it was stopped afterward. Cholestyramine Eventually, the patient's free T4 level started to decline and the day before her thyroidectomy, the free T4 level was 4.7 ng/dL ( with radioiodine, since radioiodine may exacerbate the condition. 9, 10) Worsening ophthalmopathy is more common in cigarette smokers than nonsmokers. 10) Thyroidectomy should preferably be performed when the patient is euthyroid in order to decrease perioperative cardiac risk. Adjunctive treatment in the form of beta-blockers, corticosteroids, or inorganic iodine may also be used to achieve a euthyroid state. However, in some cases, additional treatment may be required despite these conventional modalities.
Cholestyramine, an ion exchange resin used to lower serum cholesterol, interferes with the absorption of ingested thyroid hormones and the enterohepatic circulation of endogenous thyroid hormones, whose levels are increased in hyperthyroidism. 11) There are several studies regarding cholestyramine as a medication for thyrotoxicosis. Certain studies have reported a more rapid decline in free T4 and total T3 levels in patients diagnosed with Graves' disease who were treated for 4 weeks with cholestyramine and antithyroid drugs as compared to patients treated with only antithyroid drugs. 5, 12) In addition, Sebastian-Ochoa et al. 6) reported a patient who was resistant to antithyroid drug in whom thyroid hormone levels completely normalized after 1 week of additional treatment with cholestyramine. Furthermore, Kaykhaei et al. 13) suggested that low doses of cholestyramine are effective in producing a rapid and complete decline of thyroid hormone levels in patients with Graves' disease, when used in combination with MMI and propranolol. Based on these reports, cholestyramine was orally administered for rapid preoperative control of severe thyrotoxicosis in a patient who underwent surgery for excision of a toxic goiter due to Graves' disease that was refractory to treatment with propranolol and high doses of MMI.
Mercado et al. 5) reported that once the cholestyramine was discontinued after 2 weeks of the administration, the declining rate of thyroid hormones slowed down. So we think it's worth a try to prescribe cholestyramine when Graves' disease is diagnosed at the first time. The dosage of cholestyramine was variable in reports. It was administered from minimally 1 g twice a day 13) to maximally 4 g four times a day. 4) The treatment period was usually 2 to 4 weeks. Because cholestyramine showed its efficacy even it was minimally administered, we suggest to prescribe small dose of cholestyramine at the time you try it, in case the patient shows adverse effects.
However, it is necessary to consider why the patient was resistant to the antithyroid drugs. Possible reasons may include drug malabsorption, rapid drug metabolism, antidrug antibodies, impairment of intrathyroidal drug accumulation or action, and predominant elevation of T3 rather than T4 levels.
14)
Therefore, we closely monitored the management of our patient and found her to be compliant in taking her medications. There was nothing remarkable in her medical history or physical examination to suggest malabsorption. We considered measuring the drug level or detecting anti-drug antibodies in the patient's thyroid tissue, but these tests are not usually available for routine clinical use. Thus, we were not able to determine the MMI level in the patient's thyroid tissue. The glucocorticoid is known to prohibit conversion of T4 to T3 in peripheral tissues and release of thyroid hormone from the thyroid so it is used as an adjunctive treatment in thyrotoxicosis. But we couldn't find the reference that how much the steroid was able to decrease the level of free T4 and how fast.
Empirically, decline of free T4 when the glucocorticoid is used is mild.
The limitation of this case is that the effect of glucocorticoid and that of cholestyramine on free T4 can't be divided. 15) The present case highlights a rare but important, clinical finding in the treatment of antithyroid drug-resistant thyrotoxicosis. Based on our experience with this case, we conclude that in cases of thyrotoxicosis refractory to medical treatment, cholestyramine may be used as an adjuvant to antithyroid drugs for the rapid treatment of patients prior to thyroidectomy when surgery cannot be delayed. A more comprehensive study needs to be conducted in order to validate our findings.
